Luminex Corporation Unveils FlexMAP 3D(TM), the Next Generation Instrument, at AACC
July 17 2007 - 6:00AM
PR Newswire (US)
New Three-Dimensional Multiplexing System Will Offer the
Simultaneous Measurement of Up to 500 Analytes, Greater Speed, and
Simplified Workflow AUSTIN, Texas, July 17 /PRNewswire-FirstCall/
-- Luminex Corporation (NASDAQ:LMNX), the world leader in
multiplexed solutions, will unveil FlexMAP 3D(TM), its next
generation bead-based multiplexing system, today at the American
Association for Clinical Chemistry (AACC) Annual Meeting in San
Diego. FlexMAP 3D will be able to simultaneously measure up to 500
analytes in a single microplate well and provide scientists,
researchers and clinicians with improved analytical performance,
greater speed, more automation and a streamlined workflow. The new
system will be on display at Luminex's AACC booth: number 1731. "As
the worldwide leader in multiplexing solutions, our goal at Luminex
is to develop innovative and effective products that meet a range
of laboratories' needs," said Patrick J. Balthrop, president and
chief executive officer of Luminex. "The FlexMAP 3D system is an
exciting addition to our product line. We designed FlexMAP 3D for
clinical reference labs, pharmaceutical labs and academic core labs
that are interested in enhanced workflow and higher multiplexing
capabilities while maintaining the advantages of the xMAP(R)
bead-based technology. This system features the same flexibility of
our other instruments and provides increased speed, multiplexing,
sensitivity and automation." The FlexMAP 3D system expands on the
efficiencies provided by Luminex's current instruments. FlexMAP 3D
will be able to test for up to 500 analytes simultaneously, an
increase from the 100-plex capabilities of Luminex's current
offerings. The higher multiplexing capabilities will enable users
to broaden the types of testing performed using bead-based
multiplexing. In addition to increased multiplexing capabilities,
the new FlexMAP 3D will offer a high-throughput module and the
ability to interface with liquid handlers for streamlined
automation. Medium and high volume laboratories seeking more data
per sample will benefit from the increased multiplexing
capabilities. The FlexMAP 3D system will also include cutting edge
digital technology, redesigned optics for improved assay
performance, a dual syringe assembly to enhance throughput, an auto
adjusting probe and software to enable automation, and the ability
to use both 96 and 384 well plates. The new system is powered by
xPONENT 3D(TM) software and features an intuitive touch screen
interface as well as ergonomic design and a small footprint. These
features will combine to deliver users higher throughput, improved
sensitivity and accuracy, increased dynamic range, and a simplified
and optimized workflow. The Luminex systems are flexible analyzers
based on the principles of three-dimensional bead arrays. Due to
the enhanced liquid kinetics of the microspheres in solution, these
arrays offer superior uniformity and faster reaction times than
standard two-dimensional planar arrays. The proprietary microsphere
dyeing process also provides higher levels of multiplexing than
traditional methods like ELISA or real-time PCR. Luminex licenses
its instruments and array-based assays to market leading companies
in clinical diagnostics and biological research. Assays from
Luminex and its partners deliver fast and cost-effective bioassay
results in many assay formats including nucleic acid assays,
receptor-ligand assays, immunoassays and enzymatic assays.
Currently in alpha testing, FlexMAP 3D is targeted to be
commercially available in 2008. About Luminex Corporation Luminex
Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the
diagnostic and life sciences industries. The Company's xMAP(R)
multiplex solutions include an open-architecture, multi-analyte
technology platform that delivers fast, accurate and cost-effective
bioassay results to markets as diverse as pharmaceutical drug
discovery, clinical diagnostics and biomedical research, including
the genomics and proteomics markets. The Company's xMAP technology
is sold worldwide and is already in use in leading clinical
laboratories as well as major pharmaceutical, diagnostic and
biotechnology companies. Further information on Luminex Corporation
or xMAP can be obtained at http://www.luminexcorp.com/. Luminex
Corporate Contact: Harriss T. Currie Vice President, Finance and
Chief Financial Officer 512-219-8020 Luminex Media Contact: Nicole
L. Cottrill 615-327-7999 DATASOURCE: Luminex Corporation CONTACT:
Corporate, Harriss T. Currie, Vice President, Finance and Chief
Financial Officer, +1-512-219-8020, , or Media, Nicole L. Cottrill,
+1-615-327-7999, , both of Luminex
Copyright
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Luminex Corporation (NASDAQ): 0 recent articles
More Luminex (MM) News Articles